Arthur Culang Email Address

Director, Operations

Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

- Build and support biotech organizational growth from research through commercial stage - Leverage in-depth analytics and creative communications I’m a multifaceted cross-functional contributor who delivers business insights based on enterprise data analytics, commercial forecasting, and information technology implementation. I develop quantitative models and tailor external and internal communications to diverse constituencies, including executives, investors, employees, and government agencies. Highly proficient in Tableau, Excel, PowerPoint, and web design. Team management and budget ownership.